Literature DB >> 12621667

An intermittent schedule is better than continuous regimen of antimonial therapy for cutaneous leishmaniasis in the municipality of Rio de Janeiro, Brazil.

Rilza Beatriz G de Azeredo-Coutinho1, Sergio C F Mendonça.   

Abstract

This study reviews a series of cutaneous leishmaniasis cases diagnosed and treated in outpatient units in the municipality of Rio de Janeiro, where the intermittent schedule of antimonial therapy was replaced by the continuous regimen. Both schedules were based on daily intramuscular injections of pentavalent antimonial. Forty-nine subjects received the intermittent regimen, consisting of three ten-day series alternated with ten-day rest intervals whereas seventy-one patients received the continuous regimen during 20 consecutive days. The study groups had similar composition regarding age, sex and clinical condition. The cure rate was significantly higher in the group receiving the intermittent schedule than in the group receiving continuous therapy (89.8% vs 63.3%). Moreover, loss to follow-up was significantly more frequent in the group receiving continuous therapy (19.7% vs 4.1% in the intermittent therapy). Under field conditions, the intermittent regimen provided higher effectiveness and adherence than the continuous schedule.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12621667     DOI: 10.1590/s0037-86822002000500009

Source DB:  PubMed          Journal:  Rev Soc Bras Med Trop        ISSN: 0037-8682            Impact factor:   1.581


  2 in total

1.  American tegumentary leishmaniasis: epidemiological and molecular characterization of prevalent Leishmania species in the State of Tocantins, Brazil, 2011-2015.

Authors:  Carina Scolari Gosch; Cálita Pollyanna Marques; Bruna Silva Resende; Joandson Dos Santos Souza; Ray Ameida da Silva Rocha; Deyse Sabrinne Souza Lopes; Marcelo Scolari Gosch; Fátima Ribeiro Dias; Miriam Leandro Dorta
Journal:  Rev Inst Med Trop Sao Paulo       Date:  2017-12-21       Impact factor: 1.846

2.  Factors associated to adherence to different treatment schemes with meglumine antimoniate in a clinical trial for cutaneous leishmaniasis.

Authors:  Madelon Novato Ribeiro; Maria Inês Fernandes Pimentel; Armando de Oliveira Schubach; Raquel de Vasconcellos Carvalhães de Oliveira; José Liporage Teixeira; Madson Pedro da Silva Leite; Monique Fonseca; Ginelza Peres Lima dos Santos; Mariza Matos Salgueiro; Erica de Camargo Ferreira e Vasconcellos; Marcelo Rosandiski Lyra; Mauricio Naoto Saheki; Claudia Maria Valete-Rosalino
Journal:  Rev Inst Med Trop Sao Paulo       Date:  2014 Jul-Aug       Impact factor: 1.846

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.